Aug 28, 2014
The research team at Achieve Clinical is conducting a new clinical study in Birmingham, AL. People who are living with fibromyalgia may qualify to participate if they are at least 18 years of age.
Aug 27, 2014
The research team at Avail Clinical is conducting new clinical studies in DeLand, FL. People who are living with fibromyalgia may qualify to participate if they are at least 18 years of age.
Jul 17, 2014
Achieve is conducting a Phase III, randomized, placebo-controlled study to evaluate the safety and effectiveness of a new viscoelastic hydrogel, for the treatment of osteoarthritis (OA) of the knee.
Jul 15, 2014
Avail is conducting a Phase 2, randomized, placebo-controlled clinical research study to evaluate the efficacy, safety and pharmacokinetics of an experimental spray treatment for qualified participants with mild to moderate OA in the knee.
Jun 11, 2014
Achieve is conducting a multicenter, randomized, single-dose study assessing the pharmacodynamic parameters of an experimental combination therapy in patients with rheumatoid arthritis on stable methotrexate (MTX) treatment.
Jun 10, 2014
Avail is conducting a phase 1, open-label pharmacokinetic and pharmacodynamic study of a single dose of an experimental drug in subjects with hepatic impairment and in matched healthy volunteers.
May 14, 2014
Achieve is conducting a Phase 2b, multi-center study of the efficacy and safety of a topically applied experimental gel in subjects with moderate to severe pain associated with osteoarthritis (OA) of the knee following cessation of pain therapy.
May 13, 2014
Avail is conducting a phase 1, single dose, parallel group study to evaluate the pharmacokinetics of an experimental drug in subjects with impaired renal function.
Apr 16, 2014
Achieve is conducting a randomized, active and placebo-controlled study to evaluate the efficacy and safety of an experimental drug for preventing flares and reducing serum uric acid in patients with gout.
Apr 15, 2014
Avail is conducting a 6-week, Phase 2 randomized study to assess the safety, tolerability and pharmacodynamics of a new combination therapy administered to participants with type 2 diabetes mellitus.